By Colin Kellaher
Reneo Pharmaceuticals has agreed to combine with privately held OnKure in an all-stock reverse merger that will create a clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of precision cancer drugs.
Reneo on Monday said the combined company will have about $120 million of cash resources at closing, including $65 million from a planned private financing, which would provide a runway into the fourth quarter of 2026.
A reverse merger allows a private company to go public by merging with a public one at a lower cost than is involved in traditional initial public offerings.
Reneo, based in Irvine, Calif., said that excluding the financing, its shareholders will own about 31% of the combined company, while OnKure investors will own roughly 69%.
Reneo said the combined company will operate under the name OnKure Therapeutics and trade on the Nasdaq Global Market under the ticker OKUR.
The deal and private financing are slated to close later this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 13, 2024 08:13 ET (12:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。